6 Results for "

OCI-LY10 diffuse large B-cell lymphoma cells

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "OCI-LY10 diffuse large B-cell lymphoma cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-153368
CAS No.: 2655656-99-6
Purity:  95.43%
Synonyms: KT-413
Zomiradomide (KT-413) is an orally active IRAK4 PROTAC degrader with a DC50 of 6 nM. Zomiradomide inhibits the NF-κB signaling pathway, while its molecular glue function mediates the degradation of Ikaros and Aiolos (with a DC50 of 1 nM for both), activates the IFN-I signaling pathway, and selectively degrades IMiD substrates. Zomiradomide inhibits cancer cell proliferation and tumor growth. Zomiradomide can be used in research related to B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-153357
CAS No.: 2416130-57-7
Purity:  98.16%
Target:  

PROTACs Btk c-Myc NF-κB

Research Areas:  

Inflammation/Immunology Cancer

NRX-0492 is an orally active BTK PROTAC degrader, with a binding IC50 of 1.2 nM for both wild-type BTK and BTK T474I, and 2.7 nM for BTK C481S, and exhibits cellular DC50 values of 0.1 nM and 0.2 nM against wild-type BTK and BTK C481S, respectively. NRX-0492 catalyzes the ubiquitination and proteasomal degradation of wild-type and drug-resistant mutant BTK by recruiting the CRBN E3 ubiquitin ligase complex. NRX-0492 inhibits the BCR signaling pathway and its downstream NF-κB/MYC transcriptional program, achieves rapid and sustained degradation in primary CLL cells, and exhibits extremely low cytotoxicity. NRX-0492 degrades BTK, inhibits tumor cell proliferation and activation, and significantly suppresses tumor growth in xenograft models. NRX-0492 can be used in research related to chronic lymphocytic leukemia and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-178803
Target:  

BCL6 PROTACs

Research Areas:  

Cancer

PROTAC BCL6 Degrader-2 is an orally active, selective BCL6 PROTAC degrader (DC50: 0.45 nM in HEK293T cells). PROTAC BCL6 Degrader-2 promotes ubiquitination and degradation of BCL6. It exhibits anticancer activity against BCL6-dependent diffuse large B-cell lymphoma. PROTAC BCL6 Degrader-2 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-179077
CAS No.: 2416130-49-7
Research Areas:  

Cancer

PROTAC BTK/IKZF1/3 Degrader-1 is an orally active PROTAC-IMiD bifunctional protein degrader that selectively degrades BTK, IKZF1 and IKZF3. PROTAC BTK/IKZF1/3 Degrader-1 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, mediating ubiquitination and proteasome-dependent degradation of target proteins, with no obvious degrading effect on GSPT1. PROTAC BTK/IKZF1/3 Degrader-1 inhibits cancer cell proliferation, induces cancer cell apoptosis, and suppresses tumor growth. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-179075
Research Areas:  

Cancer

PROTAC BCL6/IKZF1/3 Degrader-1 is an orally active bifunctional PROTAC‑IMiD protein degrader that targets and degrades BCL6, IKZF1 and IKZF3. PROTAC BCL6/IKZF1/3 Degrader-1 induces ubiquitination and proteasome-mediated degradation of target proteins by recruiting E3 ubiquitin ligase, and triggers cell cycle arrest and apoptosis. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits favorable anti-tumor activity in diffuse large B-cell lymphoma xenograft models. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-W1115268
CAS No.: 3043925-99-8
Research Areas:  

Cancer

E3 Ligase Ligand-linker Conjugate 231 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 231 can be used for the synthesis of the PROTAC BRD9 Degrader-8 (HY-162651) .
loading...
    loading...